RG 7828

Drug Profile

RG 7828

Alternative Names: Anti-CD20/CD3 monoclonal antibody; Anti-CD20/CD3 T-cell dependent bispecific antibody; BTCT 4465A; CD20-TBD

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in Non-Hodgkin's lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 21 Jul 2015 Genentech plans a phase I trial for Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA, Canada and South Korea (NCT02500407)
  • 01 Jun 2015 Phase-I clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top